Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Jansen

Showing results (101-110 of 254) with videos related to

Pageof 26
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2019
A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsNicholas Kitchin, Shon A Remich, James Peterson, et al.
The Pediatric Infectious Disease Journal|May 12, 2015
Group A Streptococcal Carriage and Seroepidemiology in Children up to 10 Years of Age in AustraliaHelen S Marshall, Peter Richmond, Michael Nissen, et al.
Human Vaccines & Immunotherapeutics|March 4, 2021
A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of ageBrandon Essink, James Peterson, Kari Yacisin, et al.
Vaccine|February 2, 2017
SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodiesElizabeth Begier, David Joshua Seiden, Michael Patton, et al.
Msphere|August 24, 2018
Two Vaccines for <i>Staphylococcus aureus</i> Induce a B-Cell-Mediated Immune ResponseChristopher D Dupont, Ingrid L Scully, Ross M Zimnisky, et al.
Human Vaccines & Immunotherapeutics|March 1, 2014
Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trialChristine Juergens, Pierre J T de Villiers, Keymanthri Moodley, et al.
Virology|June 1, 1995
Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiaeK J Hofmann, J C Cook, J G Joyce, et al.
Msphere|December 7, 2018
A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in QuebecRodica Gilca, Philippe De Wals, Sheila M Nolan, et al.
The British Journal of Surgery|January 26, 2017
Vaccine development to prevent Staphylococcus aureus surgical-site infectionsN Mohamed, M Y Wang, J-C Le Huec, et al.
RSC Medicinal Chemistry|November 29, 2021
SAR study of 4-arylazo-3,5-diamino-1<i>H</i>-pyrazoles: identification of small molecules that induce dispersal of <i>Pseudomonas aeruginosa</i> biofilmsCharlotte U Jansen, Jesper Uhd, Jens B Andersen, et al.
Pageof 26

Showing results (101-110 of 254) with videos related to

Sort By:
Pageof 26
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 25, 2019
A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 YearsNicholas Kitchin, Shon A Remich, James Peterson, et al.
The Pediatric Infectious Disease Journal|May 12, 2015
Group A Streptococcal Carriage and Seroepidemiology in Children up to 10 Years of Age in AustraliaHelen S Marshall, Peter Richmond, Michael Nissen, et al.
Human Vaccines & Immunotherapeutics|March 4, 2021
A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of ageBrandon Essink, James Peterson, Kari Yacisin, et al.
Vaccine|February 2, 2017
SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodiesElizabeth Begier, David Joshua Seiden, Michael Patton, et al.
Msphere|August 24, 2018
Two Vaccines for <i>Staphylococcus aureus</i> Induce a B-Cell-Mediated Immune ResponseChristopher D Dupont, Ingrid L Scully, Ross M Zimnisky, et al.
Human Vaccines & Immunotherapeutics|March 1, 2014
Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trialChristine Juergens, Pierre J T de Villiers, Keymanthri Moodley, et al.
Virology|June 1, 1995
Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiaeK J Hofmann, J C Cook, J G Joyce, et al.
Msphere|December 7, 2018
A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in QuebecRodica Gilca, Philippe De Wals, Sheila M Nolan, et al.
The British Journal of Surgery|January 26, 2017
Vaccine development to prevent Staphylococcus aureus surgical-site infectionsN Mohamed, M Y Wang, J-C Le Huec, et al.
RSC Medicinal Chemistry|November 29, 2021
SAR study of 4-arylazo-3,5-diamino-1<i>H</i>-pyrazoles: identification of small molecules that induce dispersal of <i>Pseudomonas aeruginosa</i> biofilmsCharlotte U Jansen, Jesper Uhd, Jens B Andersen, et al.
Pageof 26